Full-Time

Clinical Trial Manager

Intuitive Surgical

Intuitive Surgical

10,001+ employees

Manufactures robotic surgical systems and services

No salary listed

San Carlos, CA, USA

Hybrid

Purposeful on-site work in San Carlos is expected, and the role requires travel within the United States with occasional international travel.

Bachelor's

Category
Biology & Biotech (1)
Required Skills
Robotics

Get referred to Intuitive Surgical

See people who can refer or advise you

Requirements
  • At least 3 years of hands-on clinical trial operations experience in medical devices or diagnostics, with increasing responsibility in trial delivery.
  • Experience coordinating multi-site studies and working effectively with contract research organizations and external vendors.
  • Working knowledge of Good Clinical Practice, International Council for Harmonisation requirements, essential clinical trial documentation, and clinical quality expectations, including Trial Master File completeness, monitoring oversight, and audit readiness.
  • Strong project management skills in planning, prioritization, and stakeholder management, with the ability to drive execution in a fast-paced environment.
  • A bachelor's degree in life sciences, biomedical engineering, clinical research, or a related field.
Responsibilities
  • Manage end-to-end trial execution for assigned studies, including site identification and feasibility assessment, site initiation and activation, patient enrollment and/or sample acquisition, monitoring oversight, and study close-out.
  • Own and maintain study plans, including timelines, milestones, enrollment projections, and operational deliverables, and drive cross-functional execution to meet them.
  • Coordinate and oversee contract research organizations and vendors, including scope-of-work support, budget tracking, deliverable review, and issue escalation.
  • Drive achievement of study milestones by ensuring timely site activation, high-quality data collection, protocol compliance, and completion of key study deliverables according to established timelines.
  • Coordinate study equipment deployment, shipment, tracking, maintenance, and site logistics with internal technical and field teams.
  • Support site management activities, including site communications, site onboarding and training, query resolution, and timely data entry and documentation.
  • Ensure trial compliance and data quality by supporting adherence to protocol, Good Clinical Practice, International Council for Harmonisation requirements, applicable regulations, and internal quality standards.
  • Contribute to standard operating procedures and process improvements related to site management, monitoring practices, Trial Master File oversight, and data collection workflows.
  • Identify and escalate operational risks and issues early, propose mitigations, and drive actions to resolution across the study lifecycle.
  • Partner with Regulatory, Quality, Research and Development, Biostatistics/Data Science, and Medical Affairs to align operational plans with study objectives.
  • Support development and maintenance of key trial documents, including monitoring plans, vendor plans, enrollment plans, site training materials, study trackers, and status dashboards.
  • Provide clear, regular study status updates to internal stakeholders, highlighting progress, risks, and decisions needed.
Desired Qualifications
  • An advanced degree is a plus.
  • Experience in medical imaging, digital pathology, or image-based clinical workflows.
  • Exposure to artificial intelligence-enabled medical devices, including data collection considerations and performance evaluation concepts.
  • Experience supporting reader studies, including site and reader coordination, logistics, training, and data flow.
  • Experience supporting prospective studies in operating room or procedural settings.

Intuitive Surgical designs, manufactures, and sells robotic surgical systems and provides related services and accessories for minimally invasive surgery. The core product helps surgeons perform operations with enhanced precision by guiding robotic arms controlled from a console, allowing procedures to be done through small incisions. Instruments and consumables are used with the systems and are supported by service contracts, creating a recurring revenue stream. Compared to competitors, Intuitive has a large installed base and focuses specifically on robotic-assisted surgery, combining devices, disposable instruments, and ongoing services to support hospitals and surgical centers. Its goal is to improve patient outcomes by enabling safer, less invasive procedures while expanding the use and capabilities of robotic surgery for more procedures and providers.

Company Size

10,001+

Company Stage

IPO

Headquarters

Sunnyvale, California

Founded

1995

Get referred to Intuitive Surgical

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose 19% to $2.89 billion, beating estimates on July 16.
  • Penang lease adds 316,000 square feet and 1,200 jobs, supporting Asia-Pacific growth.
  • Management kept 2026 da Vinci growth at 13.5%-15.5% and raised gross-margin guidance.

What critics are saying

  • FDA recall tracker listed multiple 2026 da Vinci Class II recalls, signaling quality-control strain.
  • Medtronic Hugo gained U.S. urology clearance in December 2025, tightening robotic-surgery competition.
  • 2027 extended instrument-use changes risk recurring revenue erosion if hospitals delay upgrades.

What makes Intuitive Surgical unique

  • Da Vinci installed base neared 13,000 systems worldwide, locking in switching costs.
  • Da Vinci 5 launched broadly in the U.S. in 2025, boosting utilization.
  • Ion procedures grew 36% in Q2 2026, extending Intuitive beyond soft-tissue robotics.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Aug 19th, 2026
Abbott beats Q2 estimates with 13% sales growth as diagnostics surge 42%, while Intuitive Surgical posts 19% revenue rise

Abbott Laboratories reported strong fiscal Q2 2026 results, with sales rising 13% on a reported basis and 4.8% on a comparable basis, beating estimates and prompting the company to raise its annual profit forecast. The diagnostics segment was particularly strong, growing 42% to $3.09 billion, driven by its cancer diagnostics business following the Exact Sciences acquisition. Intuitive Surgical also exceeded expectations in Q2 2026, with revenue growing 19% to $2.89 billion and adjusted EPS of $2.80, beating forecasts by $0.30. The company placed 468 da Vinci units during the quarter, an 18% year-over-year increase, whilst maintaining a non-GAAP gross margin of 70.0%. The companies present contrasting investment cases: Abbott offers diversified healthcare portfolio resilience, whilst Intuitive Surgical relies on its robotic surgery ecosystem with recurring revenue comprising approximately 85% of total sales.

PR Newswire
Aug 17th, 2026
Intuitive leases 316,000-sq-ft facility in Penang to manufacture surgical instruments, create 1,200 jobs by 2032

Intuitive, the global leader in minimally invasive care and pioneer of robotic-assisted surgery, has signed a lease agreement with Penang Development Corporation for a new manufacturing facility in Malaysia. The 316,000-square-foot site in Bandar Cassia Technology Park will produce surgical instruments and electromechanical devices for Intuitive's da Vinci surgical system. The facility is expected to begin operations in 2028 and create 1,200 highly skilled jobs by 2032. The investment reflects Intuitive's commitment to Asia Pacific, where its da Vinci systems have treated more than 2.5 million patients across 13 markets over two decades. The expansion aims to support growing demand for robotic-assisted surgery across the region and strengthen Penang's position as a MedTech manufacturing hub in Southeast Asia.

Yahoo Finance
Aug 16th, 2026
Oppenheimer upgrades Intuitive Surgical to 'Outperform' with $500 price target

Oppenheimer upgraded Intuitive Surgical from "Perform" to "Outperform" with a $500 price target, implying a 24.6% upside. The analysts expect the medtech company to maintain its leading position in robotic surgery despite increasing competition. Intuitive reported strong Q2 results, with revenue rising 18.5% year-over-year to $2.89 billion, surpassing analyst expectations. Non-GAAP earnings per share climbed 27.9% to $2.80, beating the $2.50 estimate. The company placed 468 da Vinci surgical systems and 55 Ion endoluminal systems during the quarter. Combined da Vinci and Ion procedures rose approximately 16% globally. Wall Street maintains a "Strong Buy" consensus rating on the stock, with 22 of 31 analysts recommending a strong buy. The consensus price target of $480.93 represents a 19.85% upside.

Yahoo Finance
Aug 12th, 2026
Intuitive Surgical's valuation barely budges despite two years of growth forecasts

Intuitive Surgical trades at $401.23, down 32% from its 52-week high and 15% over twelve months. The stock currently trades at 37.7 times trailing adjusted earnings. Analysts forecast earnings of $12.08 per share by 2027, bringing the multiple down to 33 times — only 13% lower despite two years of growth. Consensus projects 7% annual earnings growth and 9.7% revenue growth, suggesting margin compression ahead. Management raised its 2026 gross profit margin guidance to 68-69%. However, the company plans to extend instrument use limits starting in the first half of 2027 to lower procedure costs and boost adoption. Intuitive has not finalised pricing for this programme, creating uncertainty around 2027 estimates. The company will quantify the impact on its next earnings call.

Yahoo Finance
Aug 8th, 2026
Medtronic and Intuitive Surgical lag market amid sector weakness

Medtronic and Intuitive Surgical, two medical device leaders, have underperformed this year due to sector weakness and company-specific challenges. However, both show potential for recovery. Medtronic's fourth-quarter revenue rose 9.9% to $9.8 billion, though adjusted earnings per share fell 4.3% to $1.55 due to higher costs, including tariffs. The company posted its highest annual revenue growth in a decade, driven partly by its Pulse Field Ablation franchise. Medtronic recently received FDA clearance for its Hugo robotic-assisted surgery system for urologic procedures, positioning it to compete in the underpenetrated robotic surgery market. The company plans to spin off its lower-margin diabetes care division, which should improve margins. With a 3.4% forward dividend yield and 49 consecutive years of payout increases, Medtronic appeals to income-focused investors.